Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk MDS or AML (PANOBEST)
Phase of Trial: Phase I/II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Panobinostat (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms PANOBEST
- 19 Mar 2018 Planned End Date changed from 1 Aug 2017 to 1 Apr 2018.
- 19 Mar 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Apr 2018.
- 01 Sep 2016 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History